Frovatriptan versus zolmitriptan for the acute treatment of migraine: A double-blind, randomized, multicenter, Italian study

Vincenzo Tullo, Gianni Allais, Michel D. Ferrari, Marcella Curone, Eliana Mea, Stefano Omboni, Chiara Benedetto, Dario Zava, Gennaro Bussone

Research output: Contribution to journalArticlepeer-review

Abstract

The objective of this study is to assess patients' satisfaction with migraine treatment with frovatriptan (F) or zolmitriptan (Z), by preference questionnaire. 133 subjects with a history of migraine with or without aura (IHS criteria) were randomized to F 2.5 mg or Z 2.5 mg. The study had a multicenter, randomized, double-blind, crossover design, with each of the two treatment periods lasting no more than 3 months. At the end of the study, patients were asked to assign preference to one of the treatments (primary endpoint). The number of pain-free (PF) and pain-relief (PR) episodes at 2 h, and number of recurrent and sustained pain-free (SPF) episodes within 48 h were the secondary study endpoints. Seventy-seven percent of patients expressed a preference. Average score of preference was 2.9 ± 1.3 (F) versus 3.0 ± 1.3 (Z; p = NS). Rate of PF episodes at 2 h was 26% with F and 31% with Z (p = NS). PR episodes at 2 h were 57% for F and 58% for Z (p = NS). Rate of recurrence was 21 (F) and 24% (Z; p = NS). Time to recurrence within 48 h was better for F especially between 4 and 16 h (p

Original languageEnglish
JournalNeurological Sciences
Volume31
Issue numberSUPPL.1
DOIs
Publication statusPublished - Jun 2010

Keywords

  • Frovatriptan
  • Migraine
  • Patient preference
  • Zolmitriptan

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Dermatology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Frovatriptan versus zolmitriptan for the acute treatment of migraine: A double-blind, randomized, multicenter, Italian study'. Together they form a unique fingerprint.

Cite this